Daraprim 2020 U.S. PROMOTIONAL AUDIT REPORT

Published July 2021 • 21 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Daraprim through reportable promotional activity in 2020 to drive use within the Toxoplasmosis market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Vyera Pharma’s depth of coverage vary within key specialties (e.g., Infectious Disease, Ophthalmology, Internal Medicine, and Family Medicine) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Daraprim throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Daraprim in 2020?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 200 paid interactions across 200 physicians made on behalf of Daraprim were carefully examined to support our analysis.